- INTERNATIONAL COURSE: PRECISION SURGICAL PATHOLOGY.
INTERNATIONAL COURSE
SEAP-IAP
International Course: Precision Surgical Pathology.
Thursday, 23
08:30-08:35 h. Welcome.
José Palacios.
Ramón y Cajal University Hospital. Madrid. Spain. CIBERONC.
08:35-11:05 h. Session 1.
Gynaecological Pathology.
Chairperson: José Palacios.
Ramón y Cajal University Hospital. Madrid. Spain. CIBERONC.
Selected Aspects of HPV and non-HPV Related Cervical Adenocarcinomas.
Glenn McCluggage.
Belfast Health and Social Care Trust. Belfast. UK.
Molecular, Pathological and Clinical Classification of Endometrial Cancer.
Jaime Prat.
Autonomous University. Barcelona. Spain.
The spectrum of Neuroendocrine Uterine Tumours.
Esther Oliva.
Massachusetts General Hospital. Boston. USA.
Metastatic Involvement of the Female Genital Tract. Pathologic and Molecular Implications in Diagnosis and Pathogenesis.
Xavier Matías-Guiu.
Bellvitge University Hospital. Barcelona. Spain. CIBERONC.
Germ cell tumours of the female genital tract. A paradigm of neoplastic stemness.
Francisco Nogales.
University of Granada. Spain.
11:05-11:30 h. Coffee-break
11:30-13:30 h. Session 2.
Molecular and Breast Pathology.
Chairperson: José Palacios.
Ramón y Cajal University Hospital. Madrid. Spain. CIBERONC.
The Future of Precision Pathology: Considerations for Technology adoption and Training.
Manuel Salto-Téllez.
Queen's University. Belfast. UK.
Why Molecular Pathology in Breast Cancer?
Fernando Schmitt.
Medical Faculty of Porto University & Ipatimup, Porto, Portugal.
Precision Medicine: Molecular Tools Enhance the Diagnosis and Management of Breast Carcinoma.
Edi Brogi.
Memorial Sloan Kettering Cancer Center. New York. USA.
Metaplastic Carcinoma with Sarcomatous Transformation. Histogenesis, Morphology and Molecular Aspects.
Isabel Alvarado-Cabrero.
Mexican Oncology Hospital, IMSS. Mexico.
13:30-15:30 h. Lunch.
15:30-17:00 h. Session 3.
Urological Pathology (I).
Chairperson: Julián Sanz.
San Carlos Clinic Hospital. Madrid. Spain. CIBERONC.
Conflictive Issues Regarding Diagnosis and Prognosis of RCC subtypes.
Ferrán Algaba.
Fundació Puigvert. Barcelona. Spain.
New RCC Entities.
María José Merino.
National Cancer Institute. Bethesda. USA.
Spatial and Temporal Heterogenity in CCRCC.
José Ignacio López.
Cruces University Hospital. Bilbao. Spain.
17:00-18:00 h. Coffee-break
18:00-19:00 h. Session 3.
Urological Pathology (II).
Chairperson: Julián Sanz.
San Carlos Clinic Hospital. Madrid. Spain. CIBERONC.
Histopathological and Molecular Subtyping of Bladder Cancer for Prediction of Response to Classical and New Treatments.
Arndt Hartman.
University Hospital. Erlangen. Germany.
Divine Comedy of Prostate Cancer.
Dan Berney.
Queen Mary University. London. UK.
Friday, 24
08:30-11:00 h. Session 4.
Digestive and Liver Pathology.
Chairperson: Miriam Cuatrecasas.
Hospital Clinic. Barcelona. Spain.
Tumor Budding in Colorectal Cancer: Update 2019.
Alessandro Lugli.
Institute of Pathology, University of Bern, Switzerland
Hereditary GI Cancer Syndromes.
Fátima Carneiro.
Centro Hospitalar São João/Faculdade de Medicina do Porto & Ipatimup/i3S. Porto. Portugal.
Can we understand metastatic disease? The relevance of metastatic patterns in CRC patients.
Iris Nagtegaal.
Radboud University Medical Center. The Netherlands.
Non-alcoholic fatty liver disease: evolving concepts and perspectives.
Dina Tiniakos.
Institute of Cellular Medicine. Newcastle upon Tyne. UK.
Aretaieion Hospital, Athens, Greece.
Diagnosis and Differential Diagnosis of Hepatocellular Carcinoma.
Peter Schirmacher.
University Hospital. Heidelberg. Germany.
10:30-11:30 h. Coffee-break
11:30-13:30 h. Session 5.
Bone and Soft Tissue Pathology.
Chairperson: Cleofé Romagosa.
Vall d'Hebron University Hospital. Barcelona. Spain.
Diagnostic clues in Vascular tumors of Bone and Soft Tissue.
Judith Bovée.
University Hospital. Leiden University Medical Center (LUMC). The Netherlands.
Update on GIST diagnosis: morphological variants and molecular aspects.
Eva Wardelmann.
University Hospital. Münster. Germany
Cutaneous Mesenchymal Tumors: What should we know?
Víctor Prieto.
MD Anderson Cancer Center. Texas. USA.
Molecularly-defined soft tissue tumors.
Adrian Mariño.
Brigham and Women's Hospital, Harvard Medical School. Boston. USA.
13:30-15:15 h. Lunch.
15:15-17:15 h. Session 6.
Hematopathology.
Chairperson: Santiago Montes.
Marqués de Valdecilla University Hospital. Santander. Spain. CIBERONC.
Myeloproliferative neoplasms: the interplay between clinical features, morphology and molecular alterations.
Falko Fend.
University Hospital. Tuebingen. Germany.
HHV8/KSHV-Positive LPD and the spectrum of plasmablastic and plasma cell neoplasms.
Jonh Goodlad.
Queen Elizabeth University Hospital. Glasgow. UK.
B cell lymphoma. New molecular markers.
Santiago Montes.
Marqués de Valdecilla University Hospital. Santander. Spain. CIBERONC.
T cell Lymphomas and Leukemias. Genetic characterization of new entities.
Miguel Ángel Piris.
Fundación Jiménez Díaz University Hospital. Madrid. Spain.